Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

Bicycle Therapeutics plc (BCYC)

Compare

8.05

+0.20

+(2.55%)

At close: 4:00:01 PM EDT

8.19

+0.14

+(1.74%)

After hours: 5:05:41 PM EDT

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, England & BOSTON, April 02, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering in

Business Wire 11 hours ago

BCYC
+2.55%
Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, England & BOSTON, April 01, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET.

Business Wire yesterday

BCYC
+2.55%
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

CAMBRIDGE, England & BOSTON, March 27, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments.

Business Wire 6 days ago

BCYC
+2.55%
Bicycle Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Bicycle Therapeutics ( NASDAQ:BCYC ) Full Year 2024 Results Key Financial Results Revenue: US$35.3m (up 31% from FY...

Simply Wall St. last month

BCYC
+2.55%
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, England & BOSTON, February 25, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates.

Business Wire last month

BCYC
+2.55%
Bicycle Therapeutics (BCYC): Among The Small–Cap Stocks Insiders Are Selling Recently

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other small–cap stocks insiders are selling recently. Why are some investors focusing on stocks with smaller market capitalizations? Among some of the reasons are […]

Insider Monkey last month

BCYC
+2.55%
Bicycle Therapeutics (NASDAQ:BCYC) shareholders have endured a 74% loss from investing in the stock three years ago

As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...

Simply Wall St. last month

BCYC
+2.55%
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, England & BOSTON, February 05, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, at 10 a.m. ET.

Business Wire last month

BCYC
+2.55%
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

CAMBRIDGE, England & BOSTON, January 13, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and

Business Wire 2 months ago

BCYC
+2.55%
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, England & BOSTON, January 09, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT.

Business Wire 2 months ago

BCYC
+2.55%
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

On Thursday, Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium. The company revealed topline combination data for zelenectide pevedotin plus Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial ca

Benzinga 3 months ago

BCYC
+2.55%
We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 3 months ago

BCYC
+2.55%
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

CAMBRIDGE, England & BOSTON, December 12, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The

Business Wire 3 months ago

BCYC
+2.55%
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

CAMBRIDGE, England & BOSTON, December 10, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company’s clinical oncology programs.

Business Wire 3 months ago

BCYC
+2.55%
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

CAMBRIDGE, England & BOSTON, November 25, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (TNBC) patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Cancer Symposium (SABC

Business Wire 4 months ago

BCYC
+2.55%
Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025?

We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other top performing European stocks. As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index […]

Insider Monkey 4 months ago

BCYC
+2.55%
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

CAMBRIDGE, England & BOSTON, November 12, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 19, 2024, at 10:30 a.m. GMT.

Business Wire 4 months ago

BCYC
+2.55%
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Bicycle Therapeutics ( NASDAQ:BCYC ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.68m (down 50% from...

Simply Wall St. 4 months ago

BCYC
+2.55%
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

CAMBRIDGE, England & BOSTON, October 31, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the third quarter ended September 30, 2024.

Business Wire 4 months ago

BCYC
+2.55%
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

CAMBRIDGE, England & BOSTON, October 23, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of the first human imaging data validating the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrating the positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use, as we

Business Wire 5 months ago

BCYC
+2.55%

Performance Overview

Return	BCYC	MSCI WORLD (^990100-USD-STRD)
YTD	-43.03%	-1.06%
1-Year	-66.80%	+7.79%
3-Year	-81.47%	+20.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bicycle Therapeutics plc (BCYC)

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Bicycle Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Bicycle Therapeutics (BCYC): Among The Small–Cap Stocks Insiders Are Selling Recently

Bicycle Therapeutics (NASDAQ:BCYC) shareholders have endured a 74% loss from investing in the stock three years ago

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025?

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

Performance Overview